Mandate

Vinge advises Gunnebo in connection with the divestment of its Cash Management business

Vinge advises Gunnebo Aktiebolag (“Gunnebo”) in connection with the divestment of its Cash Management business to Sesami Cash Management Technologies Corporation, a cash ecosystem solution company controlled by GardaWorld Security Corporation.

The Cash Management business includes automated cash handling solutions, software and services for closed cash handling, cash recycling and cash deposit, for the purpose of creating a safer and more efficient cash cycle and reducing the cost of handling notes and coins.

The divestment is part of Gunnebo’s transformation journey started in 2020, leaving the integrated security and the cash management segments, to be able to focus on the global leading market positions within the business units Entrance Control and Safe Storage.

The transaction is expected to be closed by 1 March 2022.

Vinge’s team consisted of Christina Kokko, Matthias Pannier, Maria Dahlin Kolvik, Viktor Lennartsson and Nina Fathjalali (M&A), Mathilda Persson and Martin Boström (Commercial Agreements/IT), Stojan Arnerstål and Michael Montner (IP), and Cathrin Larsson, Sara Dahlros Sköld and Christoffer Widström (VDR).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025